EHA 2022 | 5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
Othman Al-Sawaf
• 11 Jun 2022
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, summarizes the main findings of the five-year follow-up of the CLL14 study (NCT02242942), which compares the safety and efficacy of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in previously untreated patients with chronic lymphocytic leukemia (CLL). Overall, the study showed that patients in the venetoclax arm achieved a durable remission after five years. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
